Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
84316-3-PBS targets HNF4A as part of a matched antibody pair:
MP01183-3: 84316-2-PBS capture and 84316-3-PBS detection (validated in Cytometric bead array)
Unconjugated rabbit recombinant monoclonal antibody in PBS only (BSA and azide free) storage buffer at a concentration of 1 mg/mL, ready for conjugation. Created using Proteintech’s proprietary in-house recombinant technology. Recombinant production enables unrivalled batch-to-batch consistency, easy scale-up, and future security of supply.
This conjugation ready format makes antibodies ideal for use in many applications including: ELISAs, multiplex assays requiring matched pairs, mass cytometry, and multiplex imaging applications.Antibody use should be optimized by the end user for each application and assay.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen | HNF4A fusion protein Ag24647 相同性解析による交差性が予測される生物種 |
| Full Name | hepatocyte nuclear factor 4, alpha |
| Calculated molecular weight | 53 kDa |
| Observed molecular weight | 56 kDa |
| GenBank accession number | BC137539 |
| Gene Symbol | HNF4A |
| Gene ID (NCBI) | 3172 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P41235 |
| Storage Buffer | PBS only , pH 7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
HNF4A (Hepatocyte nuclear factor 4 α) is highly conserved between humans and mice. Using conditional knockouts, epithelial HNF4A is indispensable for protecting against acute chemical-induced colitis and spontaneous colonic inflammation in aged animals (PMID:35792863). Moreover, reduced expression of HNF4A has been reported in liver fibrosis and viral vector-mediated HNF4A restoration has previously been demonstrated to reverse features of chronic liver injury. Therefore, HNF4A has been suggested as a therapeutic target for treating liver fibrosis (PMID:34453962).